HUE033210T2 - Rákellenes aktivitású 2-dezoxi-monoszacharidok új acetátjai - Google Patents
Rákellenes aktivitású 2-dezoxi-monoszacharidok új acetátjai Download PDFInfo
- Publication number
- HUE033210T2 HUE033210T2 HUE09794965A HUE09794965A HUE033210T2 HU E033210 T2 HUE033210 T2 HU E033210T2 HU E09794965 A HUE09794965 A HU E09794965A HU E09794965 A HUE09794965 A HU E09794965A HU E033210 T2 HUE033210 T2 HU E033210T2
- Authority
- HU
- Hungary
- Prior art keywords
- ddd
- autophagy
- mmol
- glucose
- benzyl
- Prior art date
Links
- 150000002772 monosaccharides Chemical class 0.000 title description 5
- 230000001093 anti-cancer Effects 0.000 title description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 150000001875 compounds Chemical class 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 229940126214 compound 3 Drugs 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 239000000243 solution Substances 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 27
- 230000034659 glycolysis Effects 0.000 description 25
- 239000003480 eluent Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 230000004900 autophagic degradation Effects 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 17
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000002274 desiccant Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 208000005017 glioblastoma Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 229960001866 silicon dioxide Drugs 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000002414 glycolytic effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- YVECGMZCTULTIS-PBXRRBTRSA-N glucal Chemical compound OC[C@H]1OC=C[C@@H](O)[C@@H]1O YVECGMZCTULTIS-PBXRRBTRSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 6
- 208000003174 Brain Neoplasms Diseases 0.000 description 6
- 206010018338 Glioma Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- JUECZQXZKZUBEY-BBBLOLIVSA-N [(2r,3s,4r)-3-acetyloxy-4-hydroxy-3,4-dihydro-2h-pyran-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC=C[C@@H](O)[C@@H]1OC(C)=O JUECZQXZKZUBEY-BBBLOLIVSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001146 hypoxic effect Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000006682 Warburg effect Effects 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 229940120638 avastin Drugs 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- -1 liquid paraffin Substances 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 230000010627 oxidative phosphorylation Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- OIWQZGBSQDJVJN-UPJWGTAASA-N (2r,3s,4r)-2-(hydroxymethyl)-3-phenylmethoxy-3,4-dihydro-2h-pyran-4-ol Chemical compound OC[C@H]1OC=C[C@@H](O)[C@@H]1OCC1=CC=CC=C1 OIWQZGBSQDJVJN-UPJWGTAASA-N 0.000 description 3
- HYSBQWOHQIVUQQ-MXWKQRLJSA-N (2r,3s,4r)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3,4-dihydro-2h-pyran-3,4-diol Chemical compound CC(C)(C)[Si](C)(C)OC[C@H]1OC=C[C@@H](O)[C@@H]1O HYSBQWOHQIVUQQ-MXWKQRLJSA-N 0.000 description 3
- ACSLJKNAGYSYRE-AQNXPRMDSA-N (2r,3s,4r)-3-phenylmethoxy-2-(phenylmethoxymethyl)-3,4-dihydro-2h-pyran-4-ol Chemical compound C([C@H]1OC=C[C@H]([C@@H]1OCC=1C=CC=CC=1)O)OCC1=CC=CC=C1 ACSLJKNAGYSYRE-AQNXPRMDSA-N 0.000 description 3
- HOMROMWVNDUGRI-RVZXSAGBSA-N (2s)-2-aminopentanedioic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O HOMROMWVNDUGRI-RVZXSAGBSA-N 0.000 description 3
- WCXVYRSRVHTPHO-VAMGGRTRSA-N (3r,4r,5r)-5,6-dihydroxy-3,4-bis(phenylmethoxy)hexanal Chemical compound O([C@H]([C@H](O)CO)[C@@H](CC=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WCXVYRSRVHTPHO-VAMGGRTRSA-N 0.000 description 3
- JWRDGLALJASVJA-AQNXPRMDSA-N (3r,4s,5r)-3,5-dihydroxy-4,6-bis(phenylmethoxy)hexanal Chemical compound C([C@@H](O)[C@@H](OCC=1C=CC=CC=1)[C@H](O)CC=O)OCC1=CC=CC=C1 JWRDGLALJASVJA-AQNXPRMDSA-N 0.000 description 3
- 102000004072 Beclin-1 Human genes 0.000 description 3
- 108090000524 Beclin-1 Proteins 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 206010064912 Malignant transformation Diseases 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- QPMIKMFBKSYRNG-SGIHWFKDSA-N [(2r,3r,4s,5r)-4-acetyloxy-2,3,5-trihydroxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](O)[C@@H](O)[C@H](OC(C)=O)[C@@H](O)C=O QPMIKMFBKSYRNG-SGIHWFKDSA-N 0.000 description 3
- UZVUBPLFXJQAEY-SDHSZQHLSA-N [(2r,3s,4r)-3,4-bis(phenylmethoxy)-3,4-dihydro-2h-pyran-2-yl]methoxy-tert-butyl-dimethylsilane Chemical compound O([C@@H]1C=CO[C@@H]([C@H]1OCC=1C=CC=CC=1)CO[Si](C)(C)C(C)(C)C)CC1=CC=CC=C1 UZVUBPLFXJQAEY-SDHSZQHLSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004957 autophagosome Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000006652 catabolic pathway Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 229940126904 hypoglycaemic agent Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000036212 malign transformation Effects 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 108700003061 poly(glutamic acid-lysine) Proteins 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XNWSEITVXQEVNP-MXWKQRLJSA-N (2r,3r,4r)-4-[tert-butyl(dimethyl)silyl]oxy-2-(hydroxymethyl)-3,4-dihydro-2h-pyran-3-ol Chemical compound CC(C)(C)[Si](C)(C)O[C@@H]1C=CO[C@H](CO)[C@H]1O XNWSEITVXQEVNP-MXWKQRLJSA-N 0.000 description 2
- DGIYKLWEVUSOLJ-FICKONGGSA-N (2r,3r,4r,5r)-2,5-dihydroxy-3,4,6-tris(phenylmethoxy)hexanal Chemical compound C([C@@H](O)[C@@H](OCC=1C=CC=CC=1)[C@H](OCC=1C=CC=CC=1)[C@@H](O)C=O)OCC1=CC=CC=C1 DGIYKLWEVUSOLJ-FICKONGGSA-N 0.000 description 2
- MXYLLYBWXIUMIT-PFBJBMPXSA-N (2r,3s,4r)-3,4-bis(phenylmethoxy)-2-(phenylmethoxymethyl)-3,4-dihydro-2h-pyran Chemical compound C([C@@H]1[C@H]([C@H](OCC=2C=CC=CC=2)C=CO1)OCC=1C=CC=CC=1)OCC1=CC=CC=C1 MXYLLYBWXIUMIT-PFBJBMPXSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- 0 CC([N+](NC(C1O)OC(*C([U])=O)CC1O)[O-])=O Chemical compound CC([N+](NC(C1O)OC(*C([U])=O)CC1O)[O-])=O 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 108091052347 Glucose transporter family Proteins 0.000 description 2
- 102000042092 Glucose transporter family Human genes 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 2
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- QIKRWYWXPRRUGN-AQNXPRMDSA-N [(2r,3s,4r)-3,4-bis(phenylmethoxy)-3,4-dihydro-2h-pyran-2-yl]methanol Chemical compound O([C@@H]1C=CO[C@@H]([C@H]1OCC=1C=CC=CC=1)CO)CC1=CC=CC=C1 QIKRWYWXPRRUGN-AQNXPRMDSA-N 0.000 description 2
- RMTDUNDTSSYUJE-KFWWJZLASA-N [(2r,3s,4r)-4-hydroxy-3-phenylmethoxy-3,4-dihydro-2h-pyran-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC=C[C@@H](O)[C@@H]1OCC1=CC=CC=C1 RMTDUNDTSSYUJE-KFWWJZLASA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006536 aerobic glycolysis Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002886 autophagic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 230000004098 cellular respiration Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 230000027721 electron transport chain Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000019261 negative regulation of glycolysis Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N phenyl acetate Chemical compound CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- HWKRAUXFMLQKLS-UHFFFAOYSA-N 2-oxidanylidenepropanoic acid Chemical compound CC(=O)C(O)=O.CC(=O)C(O)=O HWKRAUXFMLQKLS-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000906142 Balistes polylepis Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- SOLJGWBLRBOVCQ-DBIOUOCHSA-N C1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC=C1 Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC=C1 SOLJGWBLRBOVCQ-DBIOUOCHSA-N 0.000 description 1
- FGLSUAXXDAJTHQ-UHFFFAOYSA-N CCOC(CCOC1C)C1O Chemical compound CCOC(CCOC1C)C1O FGLSUAXXDAJTHQ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 125000001711 D-phenylalanine group Chemical class [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102100021808 Eukaryotic elongation factor 2 kinase Human genes 0.000 description 1
- 101710110154 Eukaryotic elongation factor 2 kinase Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- QCMJJLZRJRQCQF-KFWWJZLASA-N [(2r,3r,4r)-3-acetyloxy-4-[tert-butyl(dimethyl)silyl]oxy-3,4-dihydro-2h-pyran-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC=C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]1OC(C)=O QCMJJLZRJRQCQF-KFWWJZLASA-N 0.000 description 1
- LEKCQWLXBQDRHY-PRJMDXOYSA-N [(2r,3s,4r)-2,3,4-trihydroxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)CC=O LEKCQWLXBQDRHY-PRJMDXOYSA-N 0.000 description 1
- VXKLYMRPDFRFBV-KFWWJZLASA-N [(2r,3s,4r)-2,4-dihydroxy-6-oxo-3-phenylmethoxyhexyl] acetate Chemical compound CC(=O)OC[C@@H](O)[C@H]([C@H](O)CC=O)OCC1=CC=CC=C1 VXKLYMRPDFRFBV-KFWWJZLASA-N 0.000 description 1
- YNQILQAFUSDXOV-BBBLOLIVSA-N [(2r,3s,4r)-3-acetyloxy-2,4-dihydroxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](O)[C@@H](OC(C)=O)[C@H](O)CC=O YNQILQAFUSDXOV-BBBLOLIVSA-N 0.000 description 1
- FTHQXTNSNIOZTL-ZACQAIPSSA-N [(2r,3s,4r)-4-acetyloxy-3-phenylmethoxy-3,4-dihydro-2h-pyran-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC=C[C@@H](OC(C)=O)[C@@H]1OCC1=CC=CC=C1 FTHQXTNSNIOZTL-ZACQAIPSSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000034373 developmental growth involved in morphogenesis Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7996808P | 2008-07-11 | 2008-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE033210T2 true HUE033210T2 (hu) | 2017-11-28 |
Family
ID=41507670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE09794965A HUE033210T2 (hu) | 2008-07-11 | 2009-06-25 | Rákellenes aktivitású 2-dezoxi-monoszacharidok új acetátjai |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8927506B2 (enExample) |
| EP (1) | EP2310020B1 (enExample) |
| JP (2) | JP5677951B2 (enExample) |
| CN (1) | CN102149388B (enExample) |
| DK (1) | DK2310020T3 (enExample) |
| ES (1) | ES2628180T3 (enExample) |
| HU (1) | HUE033210T2 (enExample) |
| LT (1) | LT2310020T (enExample) |
| PL (1) | PL2310020T3 (enExample) |
| WO (1) | WO2010005799A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9149489B2 (en) | 2006-04-27 | 2015-10-06 | Board Of Regents, University Of Texas System | Inhibitors of glycolysis useful in the treatment of brain tumors |
| US8927506B2 (en) | 2008-07-11 | 2015-01-06 | Board Of Regents, The University Of Texas System | Acetates of 2-deoxy monosaccharides with anticancer activity |
| WO2012097052A2 (en) * | 2011-01-11 | 2012-07-19 | Intertech Bio, Llc | Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases |
| WO2012142615A2 (en) * | 2011-04-14 | 2012-10-18 | Board Of Regents, The University Of Texas System | Auranofin and auranofin analogs useful to treat proliferative disease and disorders |
| CN104470543A (zh) * | 2012-04-12 | 2015-03-25 | 国立大学法人岐阜大学 | 梗塞治疗用医药组合物 |
| ES2897699T3 (es) | 2013-04-05 | 2022-03-02 | Univ Texas | Esteres de 2-desoxi-monosacáridos con actividad antiproliferativa |
| WO2020035782A1 (en) * | 2018-08-13 | 2020-02-20 | Dermin Sp. Z O.O. | Molecular probes for analysis of metabolism of glycolysis inhibitors prodrugs and synthesis methods therefore |
| IL296389A (en) | 2020-03-16 | 2022-11-01 | Univ Texas | Method of treating viral infections with hexose type monosaccharides and analogs thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56103197A (en) * | 1980-01-21 | 1981-08-18 | Wakamoto Pharmaceut Co Ltd | Novel d-glucose derivative and antitumor agent containing the same as active constitutent |
| JPS58167582A (ja) | 1982-03-29 | 1983-10-03 | Takeda Chem Ind Ltd | 糖ケタ−ルの製造法 |
| US6319695B1 (en) | 1991-10-15 | 2001-11-20 | The Scripps Research Insitute | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose |
| CN1196059A (zh) * | 1995-06-23 | 1998-10-14 | 牛津糖科学(英国)有限公司 | 治疗化合物 |
| EE200200565A (et) | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
| US6670330B1 (en) | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
| CN1541106A (zh) | 2001-06-11 | 2004-10-27 | 转新疗法公司 | 用维生素b12和治疗剂联合治疗病毒性、增殖性和炎性疾病的方法 |
| WO2003018598A2 (en) | 2001-08-30 | 2003-03-06 | University College Dublin | Monosaccharide derivatives |
| WO2003082301A1 (en) | 2002-03-29 | 2003-10-09 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| AU2004204778B2 (en) * | 2003-01-10 | 2008-05-22 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| CA2431425A1 (en) | 2003-06-05 | 2004-12-05 | Angiogene, Inc. | Epas1 gene transfer to improve cell therapy |
| WO2005065721A2 (en) | 2003-12-30 | 2005-07-21 | Board Of Regents, The University Of Texas System | Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex |
| WO2006024488A2 (en) | 2004-08-30 | 2006-03-09 | Interstitial Therapeutics | Medical stent provided with inhibitors of atp synthesis |
| CN101426508A (zh) | 2006-02-24 | 2009-05-06 | 得克萨斯系统大学评议会 | 治疗癌症的己糖化合物 |
| EP1986660A4 (en) | 2006-02-24 | 2009-08-26 | Univ Texas | HEXOSE COMPOUNDS FOR CANCER TREATMENT |
| US9149489B2 (en) | 2006-04-27 | 2015-10-06 | Board Of Regents, University Of Texas System | Inhibitors of glycolysis useful in the treatment of brain tumors |
| EP1881000A1 (en) * | 2006-07-17 | 2008-01-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Conjugates of 2-fluoro-2-deoxy-glucose and their uses as anti cancer agents |
| WO2008131024A1 (en) | 2007-04-17 | 2008-10-30 | Board Of Regents, The University Of Texas System | Iodo-hexose compounds useful to treat cancer |
| US8927506B2 (en) | 2008-07-11 | 2015-01-06 | Board Of Regents, The University Of Texas System | Acetates of 2-deoxy monosaccharides with anticancer activity |
| WO2012142615A2 (en) | 2011-04-14 | 2012-10-18 | Board Of Regents, The University Of Texas System | Auranofin and auranofin analogs useful to treat proliferative disease and disorders |
-
2009
- 2009-06-25 US US13/003,429 patent/US8927506B2/en active Active
- 2009-06-25 LT LTEP09794965.5T patent/LT2310020T/lt unknown
- 2009-06-25 JP JP2011517467A patent/JP5677951B2/ja not_active Expired - Fee Related
- 2009-06-25 HU HUE09794965A patent/HUE033210T2/hu unknown
- 2009-06-25 WO PCT/US2009/048675 patent/WO2010005799A2/en not_active Ceased
- 2009-06-25 CN CN200980135924.XA patent/CN102149388B/zh not_active Expired - Fee Related
- 2009-06-25 PL PL09794965T patent/PL2310020T3/pl unknown
- 2009-06-25 ES ES09794965.5T patent/ES2628180T3/es active Active
- 2009-06-25 DK DK09794965.5T patent/DK2310020T3/en active
- 2009-06-25 EP EP09794965.5A patent/EP2310020B1/en active Active
-
2015
- 2015-01-05 JP JP2015000024A patent/JP5890043B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102149388B (zh) | 2014-11-05 |
| JP5890043B2 (ja) | 2016-03-22 |
| LT2310020T (lt) | 2017-07-25 |
| EP2310020B1 (en) | 2017-03-15 |
| ES2628180T3 (es) | 2017-08-02 |
| WO2010005799A3 (en) | 2010-04-29 |
| PL2310020T3 (pl) | 2017-10-31 |
| US20110160151A1 (en) | 2011-06-30 |
| JP5677951B2 (ja) | 2015-02-25 |
| EP2310020A2 (en) | 2011-04-20 |
| CN102149388A (zh) | 2011-08-10 |
| JP2011527678A (ja) | 2011-11-04 |
| WO2010005799A2 (en) | 2010-01-14 |
| DK2310020T3 (en) | 2017-06-26 |
| JP2015091849A (ja) | 2015-05-14 |
| US8927506B2 (en) | 2015-01-06 |
| EP2310020A4 (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2310020T3 (en) | PRESENT UNKNOWN ACETATES OF 2-DEOXY MONOSACCHARIDES WITH ANTICANCER ACTIVITY | |
| US8299033B2 (en) | Iodo-hexose compounds useful to treat cancer | |
| US20100222285A1 (en) | Method of controlling the proliferation of vascular endothelial cells and inhibiting lumen formation | |
| CN1341024A (zh) | 治疗线粒体疾病的方法 | |
| EP2583972B1 (en) | Therapeutic agent for inflammatory diseases containing adenosine n1-oxide as active ingredient | |
| EP1437358A1 (en) | Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient | |
| JP2009531301A (ja) | 癌治療のためのヘキソース化合物 | |
| Schein et al. | 3-(Tetraacetyl glucopyranos-2-yl)-1-(2-chloroethyl)-1-nitrosourea, an antitumor agent with modified bone marrow toxicity | |
| JP4754532B2 (ja) | ヒアルロン酸オリゴ糖を有効成分とする治療剤 | |
| EP1663258A2 (en) | Pharmaceutical compositions and therapeutic treatment with oligo-beta- (1,3) - glucans | |
| JPH06501483A (ja) | 寄生性原虫によって起こる疾患および新形成性疾患の治療用薬剤 | |
| WO2009143078A2 (en) | Methods of treating brain cancer using hexose compounds | |
| JP7398207B2 (ja) | Ｔｏｘｉｃ ＡＧＥｓ生成抑制剤 | |
| KR101299885B1 (ko) | 피로 회복을 위한 의약 | |
| BE1030299B1 (fr) | Application de la 5'-méthylthioadénosine dans la préparation de médicaments ou de produits de santé anti-obésité | |
| JPH0317020A (ja) | 抗ｈｉｖ剤 | |
| WO2022006673A1 (en) | Anti-cancer activity of perborate salts | |
| CN107921134B (zh) | 肿瘤基因甲基化调节剂的新用途及抗肿瘤药物 | |
| KR101499286B1 (ko) | 시난디온 ａ를 포함하는 항염증용 조성물 | |
| JP2005162634A (ja) | Ｄｎａ合成酵素阻害剤 | |
| WO2022059776A1 (ja) | オートファジー活性化剤 | |
| JPWO2019044524A1 (ja) | グルコサミン類の生物学的利用率向上方法 |